Clinical and Pathological Features of Chinese Patients with Type 2 Diabetes, Biopsy-Proven Diabetic Kidney Disease, and Rapid eGFR Decline
暂无分享,去创建一个
J Zhang | M. Cooper | Lijun Zhao | Fang Liu | Junlin Zhang | Tingli Wang | Rui Zhang | Yucheng Wu | H. Ren | Yutong Zou | Huan Xu | Yuancheng Zhao | Chunmei Qin | Yi-ting Wang | M. Cooper
[1] J. McMurray,et al. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. , 2021, The lancet. Diabetes & endocrinology.
[2] I. Hirsch,et al. The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2021, Diabetologia.
[3] T. Salvatore,et al. The Importance of Telemedicine during COVID-19 Pandemic: A Focus on Diabetic Retinopathy , 2020, Journal of diabetes research.
[4] T. Nishino,et al. Clinicopathological features of fast eGFR decliners among patients with diabetic nephropathy , 2020, BMJ open diabetes research & care.
[5] J Zhang,et al. DIABETIC RETINOPATHY, CLASSIFIED USING THE LESION-AWARE DEEP LEARNING SYSTEM, PREDICTS DIABETIC END-STAGE RENAL DISEASE IN CHINESE PATIENTS. , 2020, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[6] Lijun Zhao,et al. Implications of a Family History of Diabetes and Rapid eGFR Decline in Patients With Type 2 Diabetes and Biopsy-Proven Diabetic Kidney Disease , 2019, Front. Endocrinol..
[7] S. Bakker,et al. Canagliflozin and Renal Outcomes in Diabetic Nephropathy. , 2019, New England Journal of Medicine.
[8] R. Marfella,et al. Telemedicine for screening diabetic retinopathy: The NO BLIND Italian multicenter study , 2018, Diabetes/metabolism research and reviews.
[9] Geltrude Mingrone,et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2018, Diabetes Care.
[10] Fang Liu,et al. Diabetic retinopathy may predict the renal outcomes of patients with diabetic nephropathy , 2018, Renal failure.
[11] R. Guthrie. Canagliflozin and cardiovascular and renal events in type 2 diabetes , 2018, Postgraduate medicine.
[12] Yichun Hu,et al. Segmental Sclerosis and Extracapillary Hypercellularity Predict Diabetic ESRD. , 2017, Journal of the American Society of Nephrology : JASN.
[13] H. Parving,et al. Longitudinal Estimated GFR Trajectories in Patients With and Without Type 2 Diabetes and Nephropathy. , 2018, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[14] K. Tuttle,et al. Diabetic Kidney Disease: Challenges, Progress, and Possibilities. , 2017, Clinical journal of the American Society of Nephrology : CJASN.
[15] J. Skupień,et al. Fast renal decline to end-stage renal disease: an unrecognized feature of nephropathy in diabetes. , 2017, Kidney international.
[16] Songming Huang,et al. Renal pathological implications in type 2 diabetes mellitus patients with renal involvement. , 2017, Journal of diabetes and its complications.
[17] M. Woodward,et al. Past Decline Versus Current eGFR and Subsequent Mortality Risk. , 2016, Journal of the American Society of Nephrology : JASN.
[18] R. Wolterbeek,et al. An autopsy study suggests that diabetic nephropathy is underdiagnosed. , 2016, Kidney international.
[19] V. Rigalleau,et al. Dynamic Changes in Renal Function Are Associated With Major Cardiovascular Events in Patients With Type 2 Diabetes , 2016, Diabetes Care.
[20] E. Dassau,et al. Comment on American Diabetes Association. Approaches to Glycemic Treatment. Sec. 7. In Standards of Medical Care in Diabetes—2015. Diabetes Care 2015;38(Suppl. 1):S41–S48 , 2015, Diabetes Care.
[21] K. Ohashi,et al. Clinical and pathological predictors of estimated GFR decline in patients with type 2 diabetes and overt proteinuric diabetic nephropathy , 2015, Diabetes/metabolism research and reviews.
[22] J. Górriz,et al. The Concept and the Epidemiology of Diabetic Nephropathy Have Changed in Recent Years , 2015, Journal of clinical medicine.
[23] A. Krolewski. Progressive Renal Decline: The New Paradigm of Diabetic Nephropathy in Type 1 Diabetes , 2015, Diabetes Care.
[24] J. Skupień,et al. The early decline in renal function in patients with type 1 diabetes and proteinuria predicts the risk of end stage renal disease , 2012, Kidney international.
[25] Josef Coresh,et al. Chronic kidney disease , 2012, The Lancet.
[26] T. Nagao,et al. Histological predictors for renal prognosis in diabetic nephropathy in diabetes mellitus type 2 patients with overt proteinuria , 2012, Nephrology.
[27] Arsh K Jain,et al. Dipstick proteinuria as a screening strategy to identify rapid renal decline. , 2011, Journal of the American Society of Nephrology : JASN.
[28] Jai Radhakrishnan,et al. Pathologic classification of diabetic nephropathy. , 2010, Journal of the American Society of Nephrology : JASN.
[29] C. Schmid,et al. A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.
[30] G. Remuzzi,et al. How does proteinuria cause progressive renal damage? , 2006, Journal of the American Society of Nephrology : JASN.
[31] Zhongxin Zhang,et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. , 2004, Kidney international.
[32] H. Parving,et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. , 2001, The New England journal of medicine.